慢性肾脏病谱系中第四剂SARS-CoV-2疫苗接种后的体液免疫应答:SENCOVAC研究预设分析
SENCOVAC预设分析纳入2186例慢性肾脏病(CKD)患者,30%接种第四剂疫苗。第四剂可提高血液透析(P=0.001)和非透析CKD(P=0.014)患者抗Spike抗体滴度,使72%既往阴性患者血清学转阳;突破性COVID-19住院患者既往抗体滴度<620 UI/ml且中位值低于未住院者(P=0.020)。
要点
- 第四剂疫苗提高血液透析(P=0.001)和非透析CKD(P=0.014)患者抗Spike抗体滴度。
- 第四剂使72%既往血清学阴性患者转阳,但抗体基线低者及肾移植受者抗体滴度获益最小。
- 突破性COVID-19住院患者抗体滴度<620 UI/ml,中位值低于未住院者(P=0.020)。
核心结论
- 第四剂疫苗可提高多数CKD患者抗Spike抗体滴度或使其血清学转阳,但最需要加强接种者(抗体基线低者或肾移植受者)抗体滴度获益最小。
- 突破性COVID-19住院与低抗Spike抗体滴度相关。
研究设计与样本
- SENCOVAC研究为前瞻性、观察性、多中心研究的预设分析。
- 纳入2186例完成初始疫苗接种并接种一或两剂加强针、且在初始接种后6和12个月有抗Spike抗体检测的CKD患者(18%肾移植、8%腹膜透析、69%血液透析、5%非透析CKD)。
- 30%患者接种了第四剂疫苗。
主要发现
- 第四剂疫苗提高血液透析患者抗Spike抗体滴度(P=0.001)和非透析CKD患者抗Spike抗体滴度(P=0.014)。
- 第四剂使72%既往血清学阴性患者转阳。
- 12个月时较高抗Spike抗体滴度独立相关于反复抗原暴露(第四剂、既往突破性感染)、既往抗Spike抗体滴度和非肾移植受者。
- 137例(6%)患者发生突破性COVID-19,其中5%需住院。
- 住院患者既往抗体滴度<620 UI/ml,中位值低于未住院患者(P=0.020)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is scarce evidence on the fourth dose of severe acute respiratory syndrome coronavirus 2 vaccines in chronic kidney disease (CKD) patients. We evaluated the humoral response and effectivity of the fourth dose in the CKD spectrum: non-dialysis CKD (ND-CKD), haemodialysis (HD), peritoneal dialysis (PD) and kidney transplant (KT) recipients. METHODS: This is a prespecified analysis of the prospective, observational, multicentric SENCOVAC study. In patients with CKD who had received a complete initial vaccination and one or two boosters and had anti-Spike antibody determinations 6 and 12 months after the initial vaccination, we analysed factors associated with persistent negative humoral response and higher anti-Spike antibody titres as well as the efficacy of vaccination on coronavirus disease 2019 (COVID-19) severity. RESULTS: Of 2186 patients (18% KT, 8% PD, 69% HD and 5% ND-CKD), 30% had received a fourth dose. The fourth dose increased anti-Spike antibody titres in HD (P = .001) and ND-CKD (P = .014) patients and seroconverted 72% of previously negative patients. Higher anti-Spike antibody titres at 12 months were independently associated with repeated exposure to antigen (fourth dose, previous breakthrough infections), previous anti-Spike antibody titres and not being a KT recipient. Breakthrough COVID-19 was registered in 137 (6%) patients, 5% of whom required admission. Admitted patients had prior titres <620 UI/ml and median values were lower (P = .020) than in non-admitted patients. CONCLUSIONS: A fourth vaccine dose increased anti-Spike antibody titres or seroconverted many CKD patients, but those with the highest need for a vaccine booster (i.e. those with lower pre-booster antibody titres or KT recipients) derived the least benefit in terms of antibody titres. Admission for breakthrough COVID-19 was associated with low anti-Spike antibody titres.
引用
- Quiroga B, Soler MJ, Ortiz A, et al. Humoral response after the fourth dose of the SARS-CoV-2 vaccine in the CKD spectrum: a prespecified analysis of the SENCOVAC study. Nephrol Dial Transplant. 2023. PMID: 36423334. doi:10.1093/ndt/gfac307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。